CalciMedica (CALC) director granted 937 options at $3.26

CalciMedica, Inc. (CALC) disclosed a director stock option grant on a Form 4.

Rhea-AI Filing Summary

CalciMedica, Inc. (CALC) disclosed a director stock option grant on a Form 4. On 10/13/2025, the reporting person received a Director Stock Option (Right to Buy) for 937 shares of common stock at an exercise price of $3.26 per share, coded A for award.

The option has an expiration date of 10/12/2035 and was reported as Direct (D) ownership with 937 derivative securities beneficially owned following the transaction. The filing notes a vesting schedule: beginning October 1, 2025, 1/3 of the shares subject to the option will vest in equal monthly installments. The option was granted at a price of $0 for the derivative security, consistent with standard equity awards.

Insider Trade Summary

Grant/Award: 937 shares

Grant/Award 1 txn

Insider Glicklich Alan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	937	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 937 contracts (Direct)

Footnotes (1)

1. F1. Beginning October 1, 2025, 1/3rd of the shares subject to the option shall vest in equal monthly installments.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CalciMedica (CALC) report on this Form 4?

A director received a stock option grant for 937 shares at an exercise price of $3.26 per share on 10/13/2025.

What is the exercise price and size of the CALC director option grant?

The award covers 937 underlying shares with an exercise price of $3.26 per share.

When do the CALC director options vest?

Beginning October 1, 2025, 1/3 of the shares subject to the option vest in equal monthly installments.

What is the expiration date of the CALC director option grant?

The option expires on 10/12/2035.

How many derivative securities are beneficially owned after the transaction?

The filing lists 937 derivative securities beneficially owned following the transaction.

Was any price paid for the option grant itself?

The filing shows a derivative security price of $0 for the grant, typical for equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/14/2025 - 12:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Glicklich Alan

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST S. BLVD, #307

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$3.26	10/13/2025		A		937		(1)	10/12/2035	Common Stock	937	$0	937	D

Explanation of Responses:

1. Beginning October 1, 2025, 1/3rd of the shares subject to the option shall vest in equal monthly installments.

	/s/ John Dunn, Esq., Attorney-in-Fact	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.